Name: Paolo Di Vincenzo

New title: President of neuromodulation at Medtronic

Previous title: Senior vice president and general manager of U.S. advanced wound management at Smith+Nephew

Paolo Di Vincenzo will join Medtronic as president of the neuromodulation division, where he will lead strategic direction and day-to-day operations, the company said Wednesday.

The neuromodulation unit, comprising pain interventions and brain modulation, is a $1.69 billion business at Medtronic and part of the company’s neurosciences portfolio. 

Di Vincenzo will make the move, effective Oct. 30, from Smith+Nephew, where he was senior vice president and general manager of U.S. advanced wound management. During his nine years at Smith+Nephew, he also served in global marketing and leadership roles.

Before that, Di Vincenzo held marketing leadership positions at Systagenix, then called Acelity; Becton Dickinson; and Roche Diagnostics.

“Paolo is a results-driven leader who puts people first,” Brett Wall, president of Medtronic’s neurosciences portfolio, said in a statement. “I’m thrilled to have him join this team as Neuromodulation moves into the era of personalized medicine with sensing technology.”